PFS
LAB icon

Prospera Financial Services’s Standard BioTools LAB Stock Holding History

Prospera Financial Services’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-640
Closed -$5K – 1155
2020
Q3 		$5K Buy
+640
New +$4.42K ﹤0.01% 1288

Other funds holding LAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AI
Atom Investors Austin, Texas $1.4B AUM 23.77% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return

Prospera Financial Services's LAB Position: Q4 2020 in Review

Prospera Financial Services sold out of Standard BioTools (LAB) in Q4 2020, closing a stake of 640 shares — an estimated $5K sold.

Prospera Financial Services first reported a position in LAB in Q3 2020 and held it in 1 quarter. The position peaked at $5K in Q3 2020. 145 funds tracked by Wall St. Rank hold LAB as of Q4 2020.

  • Prospera Financial Services reported no remaining Standard BioTools position as of Q4 2020 after selling out during the quarter.
  • Prospera Financial Services sold 640 Standard BioTools shares in Q4 2020, an estimated $5K.
  • Prospera Financial Services first reported a position in Standard BioTools in Q3 2020 and held it in 1 quarter.
  • Prospera Financial Services's Standard BioTools position peaked at $5K in Q3 2020.
  • 145 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2020.

Based on Prospera Financial Services's 13F filing for Q4 2020, filed 12 Feb 2021.